As cisplatin continues to be a main component of treatment regimens for cervical cancer, it is of interest to identify novel approaches, such as anti-Mesothelin CAR-NK-92 cells, that can be applied in combination with cisplatin with the aim to potentiate the elimination of cervical cancer cells. This evidence concerns the gene MSLN and cervical carcinoma.